Results 31 to 40 of about 344,680 (247)

Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma [PDF]

, 2016
Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored.
Fillerová, Regina, Gajdoš, Petr, Kriegová, Eva, Krömer, Pavel, Kudělka, Miloš, Minařík, Jiří, Papajík, Tomáš, Pika, Tomáš, Schneiderová, Petra, Ščudla, Vlastimil   +9 more
core   +1 more source

Widespread intronic polyadenylation diversifies immune cell transcriptomes

Nature Communications, 2018
Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh, Shih-Han Lee, Adam S. Sperling, Mehmet K. Samur, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie   +8 more
doaj   +1 more source

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]

, 2014
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B, Eriksen EF, Klein B, Lipton A, Mundy GR, Schmitt CP, Shay G   +6 more
core   +1 more source

Talquetamab in multiple myeloma

Haematologica, 2023
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting.
Lawrence Liu, Amrita Krishnan
doaj   +1 more source

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Blood Advances
: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes.
E. Bridget Kim, Jack E. Malespini, Matthew Lei, Samuel S. Han, Cole W. Minsky, Andrew R. Branagan, Elizabeth K. O’Donnell, Diana Cirstea, Noopur S. Raje, Andrew J. Yee   +9 more
doaj   +1 more source

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry [PDF]

, 2016
Spanish Myeloma Group (GEM) and Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups: et al.Multiple myeloma remains largely incurable.
Blanco, Juan F., Fernández, Carlos, García-Sanz, Ramón, Gutiérrez, Norma Carmen, Lahuerta, Juan José, Lécrevisse, Quentin, Martínez-López, Joaquín, Mateos, Maria Victoria, Ocio, Enrique M., Orfao, Alberto, Paiva, Bruno, Pessoa de Magalhães, Roberto J., Pérez-Andrés, Martin, San Miguel, Jesús F., Sobral da Costa, E., Vidriales, Maria Belén   +15 more
core   +1 more source

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics

Blood Cancer Journal, 2023
Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed.
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia   +14 more
doaj   +1 more source

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities

Frontiers in Oncology, 2021
Multiple myeloma (MM) is an incurable malignancy of plasma cells that grow within a permissive bone marrow microenvironment (BMM). The bone marrow milieu supports the malignant transformation both by promoting uncontrolled proliferation and resistance to
Leona Yamamoto, Nicola Amodio, Annamaria Gulla, Kenneth Carl Anderson   +3 more
doaj   +1 more source

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy, Festuccia, Francescaromana, Fofi, Claudia, Giammarioli, Elisa, La Verde, Giacinto, Mene, Paolo, Punzo, Giorgio, Tafuri, Agostino   +7 more
core   +2 more sources

Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Blood Cancer Journal
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood.
Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S. Han, Rajib Shome, Kiyosumi Ochi, Cristina Panaroni, Keertik Fulzele, Farah Rexha, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, David T. Scadden, Noopur S. Raje   +14 more
doaj   +1 more source